验证Baveno VI标准在代偿性肝硬化且持续抗病毒应答患者中筛查和监测食管静脉曲张的作用
本研究基于法国35个中心的ANRS-CO12 CirVir队列891例乙肝或丙肝相关代偿性肝硬化患者,验证Baveno VI标准对食管静脉曲张筛查和监测的效能,并分析持续病毒学应答对门脉高压进展的影响。结果显示持续应答者中Baveno VI有利状态者均无需要治疗的静脉曲张,有利状态和持续应答均与生存独立相关。
要点
- 在持续病毒学应答患者中,Baveno VI有利状态者均无需要治疗的静脉曲张。
- 548例随访61.2个月期间19.1%出现门脉高压进展,进展时均为Baveno VI不利状态。
- 无持续应答和1级食管静脉曲张与门脉高压进展独立相关。
核心结论
- 在法国大型乙肝或丙肝相关肝硬化队列中验证了Baveno VI指南对门脉高压筛查和监测的适用性,包括获得持续抗病毒应答的患者。
研究设计与样本
- 基于ANRS CO12 CirVir队列的辅助研究,纳入法国35个中心891例经活检证实肝硬化、Child-Pugh A级、无既往并发症且无肝细胞癌的患者。
主要发现
- 200例(22.4%)获得持续病毒学应答,其中80例为Baveno VI有利状态,均无需要治疗的静脉曲张。
- 548例纳入门脉高压进展分析,随访61.2个月(四分位距39.5-80.6个月)期间105例(19.1%)出现进展。
- 无持续应答和1级食管静脉曲张与门脉高压进展独立相关,进展时所有患者均为Baveno VI不利状态。
- 获得持续应答后达到Baveno VI有利状态与门脉高压无进展相关,有利状态和持续应答均与生存独立相关。
关键数值与推荐
- Baveno VI指南推荐:肝脏硬度低于20 kPa且血小板计数高于150,000的患者避免内镜检查(有利状态)。
- Baveno VI指南推荐:肝脏硬度和血小板计数较高的患者(不利状态)接受内镜评估。
- 持续病毒学应答定义为治疗结束后12周PCR检测HCV RNA低于50 IU/mL或HBV DNA检测不到。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Management of patients with cirrhosis includes endoscopic screening and surveillance to detect esophageal varices (EV) and prevent bleeding. However, the Baveno VI guidelines recommend avoiding endoscopies for patients with liver stiffness measurements below 20 kPa and platelet counts above 150,000 (favorable Baveno VI status) and endoscopic assessment of patients with higher levels of liver stiffness and platelet counts (unfavorable Baveno VI status). We aimed to validate the Baveno VI guidelines, evaluating outcomes of patients in the ANRS-CO12 CirVir cohort with compensated cirrhosis associated with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, with or without a sustained response to antiviral therapy. METHODS: We performed an ancillary study using data from 891 patients in the ANRS CO12 CirVir cohort, treated at 35 centers in France, with HCV or HBV infection and biopsy-proven cirrhosis, Child-Pugh A scores, no previous complications, and no hepatocellular carcinoma who underwent an endoscopic procedure and had interpretable liver stiffness measurements and platelet counts. Progression of portal hypertension (PHT) was defined as the onset of varices needing treatment (VNT) or PHT-related bleeding. An sustained response to antiviral therapy was defined as undetectable level of HCV RNA by polymerase chain reaction assay (<50 IU/mL) 12 weeks after the end of treatment (SVR) or an undetectable level of HBV DNA. The primary aims were to validate the Baveno VI guidelines for screening and surveillance of EV in patients with compensated cirrhosis and to study the effects of an SVR on the progression of PHT. RESULTS: A total of 200 patients achieved an SVR (22.4%) (94 patients with HCV infection, 98 patients with HBV infection, and 8 patients with both); 80 of these patients had favorable Baveno VI status and none had VNT. Progression of PHT was studied in 548 patients; during a follow-up period of 61.2 months (interquartile range, 39.5-80.6 months), 105 of these patients (19.1%) had progression of PHT. Lack of an SVR and grade 1 EV were independently associated with progression of PHT. At the time of PHT progression, all patients had unfavorable Baveno VI status. Achieving favorable Baveno VI status after an SVR was associated with the absence of PHT progression. Favorable Baveno VI status and SVR were independently associated with survival. CONCLUSIONS: In an analysis of data from a large cohort of patients with HBV- or HCV-associated cirrhosis in France, we validated the Baveno VI guidelines on screening and surveillance of PHT, even for patients who achieved a sustained response to antiviral therapy.
引用
- Thabut D, Bureau C, Layese R, et al. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. Gastroenterology. 2019. PMID: 30768988. doi:10.1053/j.gastro.2018.11.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。